Table 1.
Patient demographics and baseline characteristics.
| Characteristic | AMD | RVO | DME | |
|---|---|---|---|---|
| N (full set analysis): | 8 eyes in 8 patients | 6 eyes in 6 patients | 20 eyes in 15 patients | |
| Age (Mean ± SD) | 77.4 ± 3.1 | 66.0 ± 11.7 | 63.3 ± 10.6 | |
| Gender: n (%) | Male | 4 (50.0%) | 3 (50.0%) | 7 (46.7%) |
| Female | 4 (50.0%) | 3 (50.0%) | 8 (53.3%) | |
| Prior therapies, n (%) | ||||
| Laser therapy: n (%) | 1 (12.5%) | 1 (16.7%) | 13 (65.0%) | |
| Avastin injection: n (%) | 6 (75.0%) | 1 (16.7%) | 16 (80.0%) | |
| Average number of treatments prior to study entry | Mean ± SD: 7.17 ± 3.3 Range: 4–13 injections |
6 times | Mean ± SD: 3.7 ± 2.6 Range: 1–12 injections |
|
| Time since last injection prior to study enrollment | Median (IQR): 2.0 months (2.25 months) Range: 1–4 months |
4 months ago | Median (IQR): 4.5 months (7 months) Range: 1–42 months |
|
N: number, AMD: Age-related macular degeneration, DME: Diabetic macular edema RVO: Retinal vein occlusion, SD: Standard deviation, IQR: Inter quartile range.